[Antitubercular agents].
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000145:classification; D003523:Cycloserine / Q000009:adverse effects / Q000627:therapeutic use; D007612:Kanamycin / Q000009:adverse effects / Q000627:therapeutic use; D009355:Neomycin / Q000627:therapeutic use; D010118:Oxytetracycline / Q000009:adverse effects / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D013307:Streptomycin / Q000494:pharmacology; D014376:Tuberculosis / Q000188:drug therapy*; D014756:Viomycin / Q000009:adverse effects / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D010455:Peptides; D007612:Kanamycin; D003523:Cycloserine; D009355:Neomycin; D012293:Rifampin; D010118:Oxytetracycline; D013307:Streptomycin; D014756:Viomycin
Tuberkulostatika. 1.